Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer

NCT07565324 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT07565324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07565324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
December 31, 2032
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive breast cancer